J&J her­alds 66% ef­fi­ca­cy for sin­gle-dose shot, but falls short of mR­NA ri­vals

J&J’s vac­cine is 66% ef­fec­tive at pre­vent­ing symp­to­matic Covid-19, the com­pa­ny an­nounced Fri­day, falling short of the rough­ly 95% ef­fi­ca­cy seen in two-dose mR­NA vac­cines but giv­ing the world its first proven sin­gle-shot in­oc­u­la­tion against the pan­dem­ic virus. The vac­cine was 72% ef­fec­tive in the US.

The vac­cine was 85% ef­fec­tive at pre­vent­ing se­vere dis­ease, J&J said. As of 28 days af­ter dos­ing, the com­pa­ny saw no hos­pi­tal­iza­tions or deaths in the vac­cine group in any re­gion, a fact CSO Paul Stof­fels em­pha­sized on a call with re­porters.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER